Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Jump to content

Tasquinimod

From Wikipedia, the free encyclopedia
Tasquinimod
Legal status
Legal status
  • Experimental
Pharmacokinetic data
Elimination half-life40 ± 16 hours[1]
Identifiers
  • 4-Hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[4-(trifluoromethyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H17F3N2O4
Molar mass406.361 g·mol−1
3D model (JSmol)
  • CN1C2=C(C(=CC=C2)OC)C(=C(C1=O)C(=O)N(C)C3=CC=C(C=C3)C(F)(F)F)O
  • InChI=1S/C20H17F3N2O4/c1-24(12-9-7-11(8-10-12)20(21,22)23)18(27)16-17(26)15-13(25(2)19(16)28)5-4-6-14(15)29-3/h4-10,26H,1-3H3 checkY
  • Key:ONDYALNGTUAJDX-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)

Tasquinimod (ABR-215050, CID 54682876) is an experimental drug currently being investigated for the treatment of solid tumors. Tasquinimod has been mostly studied in prostate cancer, but its mechanism of action suggests that it could be used to treat other cancers. Castration-resistant prostate cancer (CRPC), formerly called hormone-resistant or hormone-refractory prostate cancer, is prostate cancer that grows despite medical or surgical androgen deprivation therapy. Tasquinimod targets the tumor microenvironment and counteracts cancer development by inhibiting angiogenesis and metastasis and by modulating the immune system.[2][3][4][5] It is now in phase III development,[6][7] following successful phase II trial outcomes.[7][8][9]

History

[edit]

Collaborative studies by laboratories at Johns Hopkins School of Medicine and Active Biotech Research AB identified tasquinimod as the lead agent for developing a treatment for prostate cancer.[2][10][11] Tasquinimod was one of several second-generation quinoline-3-carboxamide variants synthesized using the drug roquinimex as a starting point, and it performed well in pre-clinical studies of cancer models.[2][11][12][13]

In April 2011, Ipsen and Active Biotech entered into a broad partnership for the co-development of tasquinimod for the treatment of cancer. Active Biotech granted Ipsen exclusive rights to commercialize tasquinimod worldwide, except in North and South America and Japan where Active Biotech retained all commercial and marketing rights.[14]

Mechanism of action

[edit]

Tasquinimod is a novel small-molecule inhibitor that targets the tumor microenvironment by controlling the accumulation and immunosuppressive, pro-angiogenic and pro-metastatic functions of regulatory myeloid cells (also called myeloid-derived suppressor cells).[2][4][5][15] It binds to and inhibits the interactions of S100A9, an immunomodulatory protein that promotes tumor development,[16] influences suppressive and pro-angiogenic cells in the tumor microenvironment,[16][17][18] and participates in the establishment of pre-metastatic niches.[17]

Tasquinimod may also target the tumor microenvironment by suppressing the tumor hypoxic response, in which genes involved in the adaptation and survival of cells during hypoxia are induced.[3] Tasquinimod reduces tumor angiogenesis; but its anti-angiogenic effects do not appear to be linked to vascular endothelial growth factor (VEGF) neutralization or VEGF receptor tyrosine kinase inhibition.[2][13]

Clinical studies

[edit]

A randomized, double-blind, placebo-controlled phase II study comparing tasquinimod with placebo in 206 men with metastatic CRPC was completed in 2009.[8] The primary endpoint in the trial was to show a difference in the number of patients with disease progression at 6 months.[8] The proportion of patients who were disease progression-free after 6 months was 69% for patients treated with tasquinimod versus 37% for placebo-treated patients (p<0.001).[8] Median progression-free survival (PFS) was significantly improved in patients treated with tasquinimod compared with patients receiving placebo (7.6 vs 3.3 months; hazard ratio [HR] 0.57; 95% confidence interval [CI] 0.39, 0.85, p=0.0042).[8] Tasquinimod thus delayed disease progression by about 4.3 months. Overall survival (OS) observed for tasquinimod-treated patients was longer than previously reported in this patient population.[9] Median overall survival was 33.4 months for the tasquinimod group versus 30.4 months for the placebo group (p=0.49).[9] Using a multivariate analysis, treatment with tasquinimod was associated with an OS advantage with a HR of 0.64 (95% CI 0.42, 0.97, p=0.034).[9] It was hypothesized that the prolongation in PFS observed with tasquinimod treatment may lead to a survival advantage in men with metastatic CRPC. Also, a stronger trend for survival benefit was seen in patients with bone metastases; 34.2 for the tasquinimod group vs 27.1 months for the placebo group (HR 0.73, 95% CI 0.46, 1.17, p=0.19).[9]

Analysis of up to 3 years of safety data from phase II studies showed that treatment-related adverse events were mild to moderate, manageable and less frequent after 2 months of therapy.[7] Adverse events observed included gastrointestinal disorders, fatigue, musculoskeletal pain as well as elevations of some laboratory parameters.[7]

A phase III randomized controlled trial called 10TASQ10[6] to confirm tasquinimod’s effect on disease progression is ongoing. More than 1,200 patients with asymptomatic to mildly symptomatic metastatic CRPC were successfully enrolled in the study, as planned in the clinical protocol.[7] The study is expected to complete in 2016.[6] Other indications are currently under investigation.[6][19]

References

[edit]
  1. ^ Bratt O, Häggman M, Ahlgren G, Nordle O, Björk A, Damber JE (October 2009). "Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer". British Journal of Cancer. 101 (8): 1233–40. doi:10.1038/sj.bjc.6605322. PMC 2768463. PMID 19755981.
  2. ^ a b c d e Isaacs JT, Pili R, Qian DZ, Dalrymple SL, Garrison JB, Kyprianou N, et al. (December 2006). "Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer". The Prostate. 66 (16): 1768–78. doi:10.1002/pros.20509. PMID 16955399. S2CID 41648965.
  3. ^ a b Isaacs JT, Antony L, Dalrymple SL, Brennen WN, Gerber S, Hammers H, et al. (February 2013). "Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment". Cancer Research. 73 (4): 1386–99. doi:10.1158/0008-5472.CAN-12-2730. PMC 3578133. PMID 23149916.
  4. ^ a b Källberg E, Vogl T, Liberg D, Olsson A, Björk P, Wikström P, et al. (2012). Lebedeva IV (ed.). "S100A9 interaction with TLR4 promotes tumor growth". PLOS ONE. 7 (3): e34207. Bibcode:2012PLoSO...734207K. doi:10.1371/journal.pone.0034207. PMC 3314596. PMID 22470535.
  5. ^ a b Jennbacken K, Welén K, Olsson A, Axelsson B, Törngren M, Damber JE, Leanderson T (June 2012). "Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050)". The Prostate. 72 (8): 913–24. doi:10.1002/pros.21495. PMID 22287276. S2CID 40707516.
  6. ^ a b c d Clinical trial number NCT01234311 for "A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer" at ClinicalTrials.gov
  7. ^ a b c d e "Active Biotech and Ipsen announce completion of recruitment of tasquinimod clinical phase III study in prostate cancer" (Press release). Active Biotech. 10 December 2012. Archived from the original on 4 January 2014. Retrieved 4 January 2014.
  8. ^ a b c d e Pili R, Häggman M, Stadler WM, Gingrich JR, Assikis VJ, Björk A, et al. (October 2011). "Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer". Journal of Clinical Oncology. 29 (30): 4022–8. doi:10.1200/JCO.2011.35.6295. PMID 21931019.
  9. ^ a b c d e Armstrong AJ, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Polikoff J, et al. (June 2012). Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: Results of long-term follow-up of a randomized phase II placebo-controlled trial (PDF). American Society of Clinical Oncology Annual Meeting. Chicago. Archived from the original (PDF) on 4 March 2016.
  10. ^ Björk P, Björk A, Vogl T, Stenström M, Liberg D, Olsson A, et al. (April 2009). Akira S (ed.). "Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides". PLOS Biology. 7 (4): e97. doi:10.1371/journal.pbio.1000097. PMC 2671563. PMID 19402754.
  11. ^ a b Isaacs JT (October 2010). "The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer". Expert Opinion on Investigational Drugs. 19 (10): 1235–43. doi:10.1517/13543784.2010.514262. PMC 4124623. PMID 20836618.
  12. ^ Dalrymple SL, Becker RE, Isaacs JT (May 2007). "The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts". The Prostate. 67 (7): 790–7. doi:10.1002/pros.20573. PMID 17373719. S2CID 41672865.
  13. ^ a b Olsson A, Björk A, Vallon-Christersson J, Isaacs JT, Leanderson T (May 2010). "Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors". Molecular Cancer. 9: 107. doi:10.1186/1476-4598-9-107. PMC 2885345. PMID 20470445.
  14. ^ "Active Biotech and Ipsen enter into a broad partnership for the co- development and commercialization of TASQ in" (Press release). Active Biotech. 18 April 2011. Archived from the original on 4 January 2014. Retrieved 4 January 2014.
  15. ^ Murdoch C, Muthana M, Coffelt SB, Lewis CE (August 2008). "The role of myeloid cells in the promotion of tumour angiogenesis". Nature Reviews. Cancer. 8 (8): 618–31. doi:10.1038/nrc2444. PMID 18633355. S2CID 20327545.
  16. ^ a b Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J, et al. (October 2008). "RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis". Carcinogenesis. 29 (10): 2035–43. doi:10.1093/carcin/bgn188. PMC 2556970. PMID 18689872.
  17. ^ a b Rafii S, Lyden D (December 2006). "S100 chemokines mediate bookmarking of premetastatic niches". Nature Cell Biology. 8 (12): 1321–3. doi:10.1038/ncb1206-1321. PMC 2955889. PMID 17139281.
  18. ^ Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G (October 2008). "Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells". Journal of Immunology. 181 (7): 4666–75. doi:10.4049/jimmunol.181.7.4666. PMC 2810501. PMID 18802069.
  19. ^ Clinical trial number NCT01743469 for "A Study With Tasquinimod Treating Patients in Four Independent Cohorts of Hepatocellular, Ovarian, Renal Cell and Gastric Cancers" at ClinicalTrials.gov
Retrieved from "https://en.wikipedia.org/w/index.php?title=Tasquinimod&oldid=1181172424"